Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2017

Open Access 01-12-2017 | Correspondence

Renal Association Clinical Practice Guideline on peritoneal dialysis in adults and children

Authors: Graham Woodrow, Stanley L. Fan, Christopher Reid, Jeannette Denning, Andrew Neil Pyrah

Published in: BMC Nephrology | Issue 1/2017

Login to get access

Abstract

These guidelines cover all aspects of the care of patients who are treated with peritoneal dialysis. This includes equipment and resources, preparation for peritoneal dialysis, and adequacy of dialysis (both in terms of removing waste products and fluid), preventing and treating infections. There is also a section on diagnosis and treatment of encapsulating peritoneal sclerosis, a rare but serious complication of peritoneal dialysis where fibrotic (scar) tissue forms around the intestine. The guidelines include recommendations for infants and children, for whom peritoneal dialysis is recommended over haemodialysis.
Immediately after the introduction there is a statement of all the recommendations. These recommendations are written in a language that we think should be understandable by many patients, relatives, carers and other interested people. Consequently we have not reworded or restated them in this lay summary. They are graded 1 or 2 depending on the strength of the recommendation by the authors, and A-D depending on the quality of the evidence that the recommendation is based on.
Appendix
Available only for authorised users
Literature
1.
Fenton SSA, Schaubel DE, Desmeules M, et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis. 1997;30(3):334–42.PubMedCrossRef
2.
Vonesh EF, Snyder JJ, Foley RN, Collins AJ. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int. 2004;66(6):2389–401.PubMedCrossRef
3.
Heaf JG, Lokkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrol Dial Transplant. 2002;17(1):112–7.PubMedCrossRef
4.
Termorshuizen F, Korevaar JC, Dekker FW, Van Manen JG, Boeschoten EW, Krediet RT. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of the Netherlands cooperative study on the adequacy of dialysis 2. J Am Soc Nephrol. 2003;14(11):2851–60.PubMedCrossRef
5.
Collins AJ, Hao W, Xia H, et al. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis. 1999;34(6):1065–74.PubMedCrossRef
6.
7.
Weinhandl ED, Foley RN, Gilbertson DT, Arneson TJ, Snyder JJ, Collins AJ. Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients. J Am Soc Nephrol. 2010;21:499–506.PubMedPubMedCentralCrossRef
8.
Mehrotra R, Chiu Y-W, Kalantar-Zadeh K, Bargman J, Vonesh E. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med. 2011;171:110–8.PubMedCrossRef
9.
Yeates K, Zhu N, Vonesh E, Trpeski T, Blake P, Fenton S. Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada. Nephrol Dial Transplant. 2012;27:3568–75.PubMedCrossRef
10.
Lukowsky LR, Mehrotra R, Kheifets L, Arah OA, Nissenson AR, Kalantar-Zadeh K. Comparing mortality of peritoneal and Hemodialysis patients in the first 2 years of dialysis therapy: a marginal structural model analysis. Clin J Am Soc Nephrol. 2013;8:619–28.PubMedPubMedCentralCrossRef
11.
Korevaar JC, Feith GW, Dekker FW, et al. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int. 2003;64(6):2222–8.PubMedCrossRef
12.
Bro S, Bjorner JB, Tofte-Jensen P, et al. A prospective, randomized multicenter study comparing APD and CAPD treatment. Perit Dial Int. 1999;19(6):526–33.PubMed
13.
Watson AR, Gartland C. Guidelines by an ad hoc European committee for elective chronic peritoneal dialysis in pediatric patients. Perit Dial Int. 2001;21:240–4.PubMed
14.
Rabindranath KS, Adams J, Ali TZ, Daly C, Vale L, AM ML. Automated vs continuous ambulatory peritoneal dialysis: a systematic review of randomized controlled trials. Nephrol Dial Transplant. 2007;22:2991–8.PubMedCrossRef
15.
Michels WM, Verduijn M, Boeschoten EW, Dekker FW, Krediet RT. Similar survival on automated peritoneal dialysis and continuous ambulatory peritoneal dialysis in a large prospective cohort. Clin J Am Soc Nephrol. 2009;4:943–9.PubMedPubMedCentralCrossRef
16.
Mehrotra R, Chiu Y-W, Kalantar-Zadeh K, Vonesh E. The outcomes of continuous ambulatory and automated peritoneal dialysis are similar. Kidney Int. 2009;76:97–107.PubMedCrossRef
17.
Hall G, Bogan A, Dreis S, et al. New directions in peritoneal dialysis patient training. Nephrol Nurs J. 2004;31(2):149–54. 59-63PubMed
18.
19.
Lewis NM, Pickering KR. Establishment of a formalized CAPD retraining program. Perit Dial Int. 1995;15:S58.
20.
Bernardini J, Piraino B. Compliance in CAPD and CCPD patients as measured by supply inventories during home visits. Am J Kidney Dis. 1998;31(1):101–7.PubMedCrossRef
21.
Ponferrada L, Prowant BF, Schmidt LM, Burrows LM, Satalowich RJ, Bartelt C. Home visit effectiveness for peritoneal dialysis patients. Anna J. 1993;20(3):333–6.PubMed
22.
Figueiredo AE, Bernadini J, Bowes E, et al. A syllabus for teaching peritoneal dialysis to patients and caregivers. Perit Dial Int. 2016;36:592–605.PubMedCrossRef
23.
Povlsen JV, Ivarsen P. Assisted automated peritoneal dialysis (AAPD) for the functionally dependent and elderly patient. Perit Dial Int. 2005;25(Suppl 3):S60–3.PubMed
24.
Brown EA, Johansson L. Dialysis options for end-stage renal disease in older people. Nephron Clinical Practice. 2011;119(Suppl 1):c10–3.PubMedCrossRef
25.
26.
Oliver MJ, Al-Jaishi AA, Dixon SN, et al. Hospitalization rates for patients on assisted peritoneal dialysis compared with in-center hemodialysis. Clin J Am Soc Nephrol. 2016;11:1606–14.PubMedPubMedCentralCrossRef
27.
Iyasere OU, Brown EA, Johansson L, et al. Quality of life and physical function in older patients on dialysis: a comparison of assisted peritonealdialysis with hemodialysis. Clin J Am Soc Nephrol. 2016;11:423–30.PubMedCrossRef
28.
29.
Mactier RA, Sprosen TS, Gokal R, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int. 1998;53(4):1061–7.PubMedCrossRef
30.
Liberek T, Topley N, Jorres A, et al. Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron. 1993;65(2):260–5.PubMedCrossRef
31.
Jorres A, Bender TO, Finn A, et al. Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. Kidney Int. 1998;54(6):2184–93.PubMedCrossRef
32.
Jörres A, Topley N, Steenweg L, Müller C, Köttgen E, Gahl GM. Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle. Am J Nephrol. 1992;12(1–2):80–5.PubMed
33.
McGregor SJ, Brock JH, Briggs JD, Junor BJ. Longitudinal study of peritoneal defence mechanisms in patients on continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int. 1989;9:115–9.PubMed
34.
Topley N. Membrane longevity in peritoneal dialysis: impact of infection and bio- incompatible solutions. Adv Ren Replace Ther. 1998;5(3):179–84.PubMedCrossRef
35.
Topley N, Alobaidi HM, Davies M, Coles GA, Williams JD, Lloyd D. The effect of dialysate on peritoneal phagocyte oxidative metabolism. Kidney Int. 1988;34(3):404–11.PubMedCrossRef
36.
Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol. 2001;12(5):1046–51.PubMed
37.
Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int. 2004;66:2437–45.PubMedCrossRef
38.
Williams JD, Craig KJ, Topley N, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13(2):470–9.PubMed
39.
Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant. 1998;13(1):154–9.PubMedCrossRef
40.
Lee HY, Kim BS, Choi HY, et al. Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korea. Nephrology (Carlton). 2003;8(Suppl):S33–9.CrossRef
41.
Rippe B, Wieslander A, Musi B. Long-term results with low glucose degradation product content in peritoneal dialysis fluids. Contrib Nephrol. 2003;140:47–55.CrossRef
42.
Jones S, Holmes CJ, Krediet RT, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int. 2001;59(4):1529–38.PubMedCrossRef
43.
Jones S, Holmes CJ, Mackenzie RK, et al. Continuous dialysis with bicarbonate/lactate-buffered peritoneal dialysis fluids results in a long-term improvement in ex vivo peritoneal macrophage function. J Am Soc Nephrol. 2002;13(Suppl 1):S97–103.PubMed
44.
Williams JD, Topley N, Craig KJ, et al. The euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int. 2004;66(1):408–18.PubMedCrossRef
45.
Marshall J, Jennings P, Scott A, Fluck RJ, McIntyre CW. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int. 2003;64(4):1480–6.PubMedCrossRef
46.
Lee HY, Park HC, Seo BJ, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (balance). Perit Dial Int. 2005;25(3):248–55.PubMed
47.
Han SH, Ahn SV, Yun JY, Tranaeus A, Han D-S. Mortality and technique failure in peritoneal dialysis using advanced peritoneal dialysis solutions. Am J Kidney Dis. 2009;54:711–20.PubMedCrossRef
48.
Ahmad S, Sehmi JS, Ahmad-Zakhi KH, Clemenger M, Levy JB, Brown EA. Impact of new dialysis solutions on peritonitis rates. Kidney Int. 2006;70:S63–6.CrossRef
49.
Montenegro J, Saracho R, Gallardo I, Martínez I, Muñoz R, Quintanilla N. Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrol Dial Transplant. 2007;22:1703–8.PubMedCrossRef
50.
Johnson DW, Brown FG, Clarke M, et al. The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment and outcomes: the BalANZ trial. Perit Dial Int. 2012;32:497–506.PubMedPubMedCentralCrossRef
51.
Cho Y, Badve SV, Hawley CM, et al. Association of biocompatible peritoneal dialysis solutions with peritonitis risk, treatment and outcomes. J Am Soc Nephrol. 2013;8:1556–63.CrossRef
52.
53.
Johnson DW, Brown FG, Clarke M, et al. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal function: the balANZ trial. Nephrol Dial Transplant. 2012;27:4445–53.PubMedPubMedCentralCrossRef
54.
Johnson DW, Brown FG, Clarke M, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol. 2012;23:1097–107.PubMedPubMedCentralCrossRef
55.
Davies SJ. Preserving residual renal function in peritoneal dialysis: volume or biocompatibility? Nephrol Dial Transplant. 2009;24:2620–2.PubMedCrossRef
56.
Seo E-Y, An SH, Cho JH, et al. Effect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials. Perit Dial Int. 2014;34:724–31.PubMedPubMedCentralCrossRef
57.
Yohanna S, Alkatheeri AMA, Brimble SK et al. Effect of neutral-pH, low-glucose degradation product, peritoneal dialysis solutions on residual renal function, urine volume and ultrafiltration: A systematic review and meta-analysis. Clin J Am Soc Nephrol. 2015. published ahead of print June 5 2015. https://​doi.​org/​10.​2215/​CJN.​05410514.
58.
Chen S-Y, Chen T-W, Lin S-H, Chen C-J, Yu Y-C, Kin C-H. Does previous abdominal surgery increase postoperative complication rates in continuous ambulatory peritoneal dialysis? Perit Dial Int. 2007;27:557–9.PubMed
59.
Povlsen JV, Ivarsen P. How to start late referred ESRD patient urgently on chronic APD. Nephrol Dial Transplant. 2006;21(Suppl 2):ii56–9.PubMedCrossRef
60.
Lobbedez T, Lecouf A, Ficheux M, Henri P, de Ligny BH, Ryckelynck J-P. Is rapid initiation of peritoneal dialysis feasible in unplanned dialysis patients? A single-centre experience. Nephrol Dial Transplant. 2008;23:3290–4.PubMedCrossRef
61.
Arramreddy R, Zheng S, Saxena AB, Liebman SE, Wong L. Urgent-start peritoneal dialysis: a chance for a new beginning. Am J Kidney Dis. 2014;63:390–5.PubMedCrossRef
62.
Gokal R, Alexander S, Ash S, et al. Peritoneal catheters and exit-site practices toward optimum peritoneal access: 1998 update. (official report from the International Society for Peritoneal Dialysis). Perit Dial Int. 1998;18(1):11–33.PubMed
63.
Flanigan M, Gokal R. Peritoneal catheters and exit-site practices toward optimum peritoneal access: a review of current developments. Perit Dial Int. 2005;25(2):132–9.PubMed
64.
Crabtree JH. Rescue and salvage procedures for mechanical and infectious complications of peritoneal dialysis. Int J Artif Organs. 2006;29(1):67–84.PubMed
65.
Shah H, Chu M, Bargman JM. Perioperative management of peritoneal dialysis patients undergoing hernia surgery without use of interim hemodialysis. Perit Dial Int. 2006;26:684–7.PubMed
66.
Churchill DN, Taylor DW, Keshaviah PR. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcome. J Am Soc Nephrol. 1996;7:198–207.
67.
Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol. 2001;12(10):2158–62.PubMed
68.
Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002;13(5):1307–20.PubMed
69.
Lo WK, Ho YW, Li CS, et al. Effect of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study. Kidney Int. 2003;64(2):649–56.PubMedCrossRef
70.
Davies SJ, Phillips L, Russell L, Naish PF, Russell GI. An analysis of the effects of increasing delivered dialysis treatment to malnourished peritoneal dialysis patients. Kidney Int. 2000;57(4):1743–54.PubMedCrossRef
71.
Jansen MA, Termorshuizen F, Korevaar JC, Dekker FW, Boeschoten E, Krediet RT. Predictors of survival in anuric peritoneal dialysis patients. Kidney Int. 2005;68(3):1199–205.PubMedCrossRef
72.
Brown EA, Davies SJ, Heimburger O, et al. Adequacy targets can be met in anuric patients by automated peritoneal dialysis: baseline data from EAPOS. Perit Dial Int. 2001;21(Suppl 3):S133–7.PubMed
73.
Rumpsfeld M, McDonald SP, Johnson DW. Peritoneal small solute clearance is non-linearly related to patient survival in the Australian and New Zealand peritoneal dialysis patient populations. Perit Dial Int. 2009;29:637–46.PubMed
74.
Kim DJ, Do JH, Huh WS, Kim YG, Oh HY. Dissociation between clearances of small and middle molecules in incremental peritoneal dialysis. Perit Dial Int. 2001;21:462–6.PubMed
75.
Fischbach M, Stefanidis CJ, Watson AR. Guidelines by an ad hoc European committee on the adequacy of the paediatric peritoneal dialysis prescription. Nephrol Dial Transplant. 2002;17:380–5.PubMedCrossRef
76.
77.
Rees L, Shaw V. Nutrition in children with CRF and on dialysis. Paediatric Nephrol. 2007;22:1689–702.CrossRef
78.
Twardowski ZJ, Nolph KD, Khanna R, et al. Peritoneal Equilibration Test. Perit Dial Bull. 1987;7:138–47.
79.
Smit W, van Dijk P, Langedijk MJ, et al. Peritoneal function and assessment of reference values using a 3.86% glucose solution. Perit Dial Int. 2003;23(5):440–9.PubMed
80.
Smit W, Schouten N, van den Berg N, Langedijk MJ, Struijk DG, Krediet RT. Analysis of the prevalence and causes of ultrafiltration failure during long-term peritoneal dialysis: a cross-sectional study. Perit Dial Int. 2004;24(6):562–70.PubMed
81.
Selgas R, Bajo MA, Cirugeda A, et al. Ultrafiltration and small solute transport at initiation of PD : questioning the paradigm of peritoneal function. Perit Dial Int. 2005;25(1):68–76.PubMed
82.
Davies SJ, Phillips L, Naish PF, Russell G. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant. 2002;17(6):1085–92.PubMedCrossRef
83.
Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Page D. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. J Am Soc Nephrol. 1998;9:1285–92.PubMed
84.
Rumpsfeld M, McDonald SP, Johnson DW. Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. J Am Soc Nephrol. 2006;17(1):271–8. Epub 2005 Nov 23PubMedCrossRef
85.
Brown EA, Davies SJ, Rutherford P, et al. Survival of functionally Anuric patients on automated peritoneal dialysis: the European APD outcome study. J Am Soc Nephrol. 2003;14(11):2948–57.PubMedCrossRef
86.
Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG. Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol. 2006;17(9):2591–8. Epub 006 Aug 2PubMedCrossRef
87.
Heimburger O, Wang T, Lindholm B. Alterations in water and solute transport with time on peritoneal dialysis. Perit Dial Int. 1999;19(Suppl 2):S83–90.PubMed
88.
del Peso G, Fernandez-Reyes MJ, Hevia C, et al. Factors influencing peritoneal transport parameters during the first year on peritoneal dialysis: peritonitis is the main factor. Nephrol Dial Transplant. 2005;20(6):1201–6.PubMedCrossRef
89.
Van Biesen W, Heimburger O, Krediet R, Rippe B, La Milia V, Covic A, Vanholder R, for the ERBP working group on peritoneal dialysis. Evaluation of peritoneal membrane characteristics: a clinical advice for prescription management by the ERBP working group. Nephrol Dial Transplant 2010 (in press).
90.
Ates K, Nergizoglu G, Keven K, et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int. 2001;60(2):767–76.PubMedCrossRef
91.
Paniagua R, Amato D, Mulais S, Vonesh E, Ramos A, Correa-Rotter R, Horl WH. Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial. Clin J Am Soc Nephrol. 2008;3:407–15.PubMedPubMedCentralCrossRef
92.
Posthuma N, ter Wee PM, Verbrugh HA, et al. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol Dial Transplant. 1997;12(3):550–3.PubMedCrossRef
93.
Plum J, Gentile S, Verger C, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis. 2002;39(4):862–71.PubMedCrossRef
94.
Wolfson M, Piraino B, Hamburger RJ, Morton AR. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis. 2002;40(5):1055–65.PubMedCrossRef
95.
Ota K, Akiba T, Nakao T, et al. Peritoneal ultrafiltration and serum icodextrin concentration during dialysis with 7.5% icodextrin solution in Japanese patients. Perit Dial Int. 2003;23(4):356–61.PubMed
96.
Finkelstein F, Healy H, Abu-Alfa A, et al. Superiority of icodextrin compared with 4.25+ACU- dextrose for peritoneal ultrafiltration. J Am Soc Nephrol. 2005;16(2):546–54.PubMedCrossRef
97.
Konings CJ, Kooman JP, Schonck M, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int. 2003;63(4):1556–63.PubMedCrossRef
98.
Davies SJ, Woodrow G, Donovan K, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol. 2003;14(9):2338–44.PubMedCrossRef
99.
Davies SJ. Mitigating peritoneal membrane characteristics in modern PD therapy. Kidney Int. 2006;103:S76–83.CrossRef
100.
Johnson DW, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins K, Bannister KM, Badve SV. Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2010;25:1973–9.PubMedCrossRef
101.
Han SH, Ahn SV, Yun JY, Tranaeus A, Han D-S. Effects of icodextrin on patient survival and technique success in patients undergoing peritoneal dialysis. Nephrol Dial Transplant. 2012;27:2044–50.PubMedCrossRef
102.
Cho Y, Johnson DW, Badve S, Craig JC, Strippoli GFK, Wiggins KJ. Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials. Nephrol Dial Transplant. 2013;28:1899–907.PubMedCrossRef
103.
Davies SJ, Brown EA, Frandsen NE, et al. Longitudinal membrane function in functionally anuric patients treated with APD : data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int. 2005;67(4):1609–15.PubMedCrossRef
104.
Fernstrom A, Hylander B, Moritz A, Jacobsson H, Rossner S. Increase of intra-abdominal fat in patients treated with continuous ambulatory peritoneal dialysis. Perit Dial Int. 1998;18(2):166–71.PubMed
105.
Van V, Schoonjans RS, Struijk DG, et al. Influence of dialysate on gastric emptying time in peritoneal dialysis patients. Perit Dial Int. 2002;22(1):32–8.PubMed
106.
de Moraes TP, Andreoli MCC, Canziani ME, et al. Icodextrin reduces insulin resistance in non-diabetic patients undergoing automated peritoneal dialysis: results of a randomized controlled trial (STARCH). Nephrol Dial Transplant. 2015;30:1905–11.PubMedCrossRef
107.
Selby NM, Fonseca S, Hulme L, Fluck RJ, Taal MW, McIntyre CW. Hypertonic glucose-based peritoneal dialysate is associated with higher blood pressure and adverse haemodynamics as compared with icodextrin. Nephrol Dial Transplant. 2005;20(9):1848–53.PubMedCrossRef
108.
Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 2001;59(3):1128–33.PubMedCrossRef
109.
Gunal AI, Duman S, Ozkahya M, et al. Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis. 2001;37(3):588–93.PubMedCrossRef
110.
Li PK, Chow KM, Wong TY, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med. 2003;139(2):105–12.PubMedCrossRef
111.
Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis. 2004;43(6):1056–64.PubMedCrossRef
112.
113.
114.
Davies SJ, Brown E, Riegel W, et al. What is the link between poor ultrafiltration and increased mortality in anuric APD patients? Analysis of data from EAPOS. Perit Dial Int. 2006;26(4):458–65.PubMed
115.
Dombros N, Dratwa M, Feriani M, et al. European best practice guidelines for peritoneal dialysis. 7 adequacy of peritoneal dialysis. Nephrol Dial Transplant. 2005;20(Suppl 9):ix24–ix7.PubMed
116.
Li PK-T, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36:481–508.PubMedCrossRef
117.
Piraino B, Bernadini J, Brown EA, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int. 2011;31:614–30.PubMedCrossRef
118.
Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. Perit Dial Int. 2012;32:S39–86.CrossRef
119.
Szeto CC, Li PK-T, Johnson DW, et al. ISPD catheter-related infection recommendations: 2017 update. Perit Dial Int. 2017;37:141–54.PubMedCrossRef
120.
Bernadinini J, Price V, Figueiredo A. Peritoneal dialysis patient training, 2006. Perit Dial Int. 2006;26:625–32.
121.
Chow KM, Szeto CC, Law MC, Fung JSF, Li PK-T. Influence of peritoneal dialysis training nurses’ experience on peritonitis rates. Clin J Am Soc Nephrol. 2007;2:647–52.PubMedCrossRef
122.
Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of Staphylococcus Aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis. 1996;27(5):695–700.PubMedCrossRef
123.
Piraino B. Staphylococcus Aureus infections in dialysis patients: focus on prevention. ASAIO J. 2000;46(6):S13–7.PubMedCrossRef
124.
Xu G, Tu W, Xu C. Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Nephrol Dial Transplant. 2010;25:587–92.PubMedCrossRef
125.
Bernardini J, Bender F, Florio T, et al. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol. 2005;16(2):539–45. Epub 2004 Dec 29PubMedCrossRef
126.
Li PK-T, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int. 2010;30:393–423.PubMedCrossRef
127.
128.
Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis. 2003;42(6):1253–9.PubMedCrossRef
129.
Kwan TH, Tong MK, Siu YP, Leung KT, Luk SH, Cheung YK. Ultrasonography in the management of exit site infections in peritoneal dialysis patients. Nephrology (Carlton). 2004;9:348–52.CrossRef
130.
Panigua R, Ventura M-d-J, Avila-Díaz M, Cisneros A, Vicenté-Martinez M, Furlong M-d-C, Garcia-Gonzalez Z, Villanueva D, Orihuela O, Prado-Uribe M-d-C, Alcantara G, Amato D. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit Dial Int. 2009;29:422–32.
131.
Li PKT, Culleton BF, Ariza A, et al. Randomised, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. J Am Soc Nephrol. 2013;24:1889–900.PubMedPubMedCentralCrossRef
132.
Stein A, Moorhouse J, Iles-Smith H, et al. Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int. 1997;52(4):1089–95.PubMedCrossRef
133.
Szeto CC, Wong TY, Chow KM, Leung CB, Li PK. Oral sodium bicarbonate for the treatment of metabolic acidosis in peritoneal dialysis patients: a randomized placebo-control trial. J Am Soc Nephrol. 2003;14(8):2119–26.PubMedCrossRef
134.
Coles GA, Gokal R, Ogg C, et al. A randomized controlled trial of a bicarbonate- and a bicarbonate/lactate-containing dialysis solution in CAPD. Perit Dial Int. 1997;17(1):48–51.PubMed
135.
Mujais S. Acid base profile in patients on PD. Kidney Int. 2003;64(Suppl. 88):S26–36.CrossRef
136.
Otte K, Gonzalez MT, Bajo MA, et al. Clinical experience with a new bicarbonate (25 mmol/L)/lactate (10 mmol/L) peritoneal dialysis solution. Perit Dial Int. 2003;23(2):138–45.PubMed
137.
Dratwa M, Wilkie M, Ryckelynck JP, et al. Clinical experience with two physiologic bicarbonate/lactate peritoneal dialysis solutions in automated peritoneal dialysis. Kidney Int. 2003;88:S105–13.CrossRef
138.
Kopple JD, Bernard D, Messana J, et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int. 1995;47(4):1148–57.PubMedCrossRef
139.
Li FK, Chan LY, Woo JC, et al. A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis. 2003;42(1):173–83.PubMedCrossRef
140.
Jones M, Hagen T, Boyle CA, et al. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study. Am J Kidney Dis. 1998;32(5):761–9.PubMedCrossRef
141.
Little J, Phillips L, Russell L, Griffiths A, Russell GI, Davies SJ. Longitudinal lipid profiles on CAPD : their relationship to weight gain, comorbidity, and dialysis factors. J Am Soc Nephrol. 1998;9(10):1931–9.PubMed
142.
Choi SJ, Kim NR, Hong SA, et al. Changes in body fat mass in patients after starting peritoneal dialysis. Perit Dial Int. 2011;31:67–73.PubMedCrossRef
143.
van Biesen W, Claes K, Covic A, et al. A multicentric, international matched pair analysis of body composition in peritoneal dialysis versus haemodialysis patients. Nephrol Dial Transplant. 2013;28:2620–8.PubMedCrossRef
144.
deMoraes TP, Andreoli MCC, Canziani ME, et al. Icodextrin reduces insulin resistance in non-diabetic patients undergoing automated peritoneal dialysis: results of a randomized controlled trial: STARCH. Nephrol Dial Transplant. 2015;30:1905–11.CrossRef
145.
KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Chapter 2: Pharmacological cholesterol-lowering treatment in adults. Kidney International Supplements 2013 (Suppl 3), 271–279.
146.
Lee JE, Oh K-H, Choi KH, et al. Statin therapy is associated with improved survival in incident peritoneal dialysis patients: propensity-matched comparison. Nephrol Dial Transplant. 2011;26:4090–4.PubMedCrossRef
147.
Blake PG, Bargman JM, Brimble KS, et al. Clinical practice guidelines and recommendations on peritoneal dialysis adequacy 2011. Perit Dial Int. 2011;31:218–39.PubMed
148.
Schoenicke G, Grabensee B, Plum J. Dialysis with icodextrin interferes with measurement of serum alpha-amylase activity. Nephrol Dial Transplant. 2002;17(11):1988–92.PubMedCrossRef
149.
Wang R, Leesch V, Turner P, Moberly JB, Martis L. Kinetic analysis of icodextrin interference with serum amylase assays. Adv Perit Dial. 2002;18:96–9.PubMed
150.
Anderstam B, Garcia-Lopez E, Heimburger O, Lindholm B. Determination of alpha-amylase activity in serum and dialysate from patients using icodextrin-based peritoneal dialysis fluid. Perit Dial Int. 2003;23(2):146–50.PubMed
151.
Garcia-Lopez E, Anderstam B, Heimburger O, Amici G, Werynski A, Lindholm B. Determination of high and low molecular weight molecules of icodextrin in plasma and dialysate, using gel filtration chromatography, in peritoneal dialysis patients. Perit Dial Int. 2005;25(2):181–91.PubMed
152.
Wens R, Taminne M, Devriendt J, et al. A previously undescribed side effect of icodextrin: overestimation of glycemia by glucose analyzer. Perit Dial Int. 1998;18(6):603–9.PubMed
153.
Oyibo SO, Pritchard GM, McLay L, et al. Blood glucose overestimation in diabetic patients on continuous ambulatory peritoneal dialysis for end-stage renal disease. Diabet Med. 2002;19(8):693–6.PubMedCrossRef
154.
Mehmet S, Quan G, Thomas S, Goldsmith D. Important causes of hypoglycaemia in patients with diabetes on peritoneal dialysis. Diabet Med. 2001;18(8):679–82.PubMedCrossRef
155.
Janssen W, Harff G, Caers M, Schellekens A. Positive interference of icodextrin metabolites in some enzymatic glucose methods. Clin Chem. 1998;44(11):2379–80.PubMed
156.
Latus J, Ulmer C, Fritz P, et al. Phenotypes of encapsulating peritoneal sclerosis - macroscopic appearance, histologic findings and outcome. Perit Dial Int. 2013;33:495–502.PubMedPubMedCentralCrossRef
157.
Krediet RT, Struijk DG, Boeschoten EW, et al. The time course of peritoneal transport kinetics in continuous ambulatory peritoneal dialysis patients who develop sclerosing peritonitis. Am J Kidney Dis. 1989;4:299–307.CrossRef
158.
Yamamoto R, Nakayama M, Hasegawa T, et al. High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis. Adv Perit Dial. 2002;18:131–4.PubMed
159.
Balasubramaniam G, Brown EA, Davenport A, et al. The pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant. 2009;24:3209–15.PubMedCrossRef
160.
Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis and treatment. Perit Dial Int. 2000;20(Suppl 4):S43–55.PubMed
161.
Nakamoto H. Encapsulating peritoneal sclerosis - a clinician’s guide to diagnosis and medical management. Perit Dial Int. 2005;25(Suppl 4):S30–8.PubMed
162.
163.
Watson CJE, Butler AJ, Bradley JA. Classification of encapsulating peritoneal sclerosis is important but must encapsulate the entire spectrum of the disease. Perit Dial Int. 2013;33:479–81.PubMedPubMedCentralCrossRef
164.
Shroff R, Stefanidis CJ, Askiti V, et al. Encapsulating peritoneal sclerosis in children on chronic PD: a survey from the European Paediatric dialysis working group. Nephrol Dial Transplant. 2013;28:1908–14.PubMedCrossRef
165.
Hoshii S, Honda M, Itami N, et al. Sclerosing encapsulating peritonitis in pediatric peritoneal dialysis patients. Pediatr Nephrol. 2000;14:275–9.PubMedCrossRef
166.
167.
Hur J, Kim KW, Park MS, Yu JS. Abdominal cocoon: preoperative diagnostic clues from radiologic imaging and pathologic correlation. Am J Roentgenol. 2004;182:639–41.CrossRef
168.
Krestin GP, Kacl G, Hauser M, Kesch G, Burger HR, Hoffman R. Imaging diagnosis of sclerosing peritonitis and relation of radiologic signs to the extent of the disease. Abdom Imaging. 1995;20:414–20.PubMedCrossRef
169.
Korzets A, Korztes Z, Peer G, et al. Sclerosing peritonitis. Possible early diagnosis by computerised tomography of the abdomen. Am J Nephrol. 1988;8:143–6.PubMedCrossRef
170.
Stafford-Johnson DB, Wilson TE, Francis IR, Swartz R. CT appearance of sclerosing peritonitis in patients with chronic ambulatory peritoneal dialysis. J Comput Assist Tomog. 1998;22:295–9.CrossRef
171.
Tarzi RM, Lim A, Moser S, et al. Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis. CJASN. 2008;3:1702–10.PubMedPubMedCentralCrossRef
172.
Vlijm A, Stoker J, Bipat S, Spijkerboer AM, Phoa SSKS, Maes R, Struijk DG. And. Krediet RT. computed tomographic findings characteristic for encapsulating peritoneal sclerosis: a case control study. Perit Dial Int. 2009;29:517–22.PubMed
173.
Hollman AS, McMillan MA, Briggs JD, Junor BJ, Morley P. Ultrasound changes in sclerosing peritonitis following continuous ambulatory dialysis. Clin Radiol. 1991;43:176–9.PubMedCrossRef
174.
Goodlad C, Tarzi R, Gedroyc W, Lim A, Moser S, Edwina A. Brown EA. Screening for encapsulating peritoneal sclerosis in patients on peritoneal dialysis: role of CT scanning. Nephrol Dial Transplant 2011; 26: 1374-1379.
175.
Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int. 2005;25(Suppl 4):S39–47.PubMed
176.
Kawanishi H, Moriishi M, Ide K, Dohi K. Recommendation of the surgical option for treatment of encapsulating peritoneal sclerosis. Perit Dial Int. 2008;28(Suppl 3):S205–10.PubMed
177.
Kawanishi H, Shintaku S, Moriishi M, Dohi K, Tsuchiya S. Seventeen years’ experience of surgical options for encapsulating peritoneal sclerosis. Adv Perit Dial. 2011;27:53–8.PubMed
178.
Kawanishi H, Kawaguchi Y, Fukui H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective controlled multicenter study. Am J Kidney Dis. 2004;44:729–37.PubMedCrossRef
179.
De Freitas D, Jordaan A, Williams R, et al. Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis. Perit Dial Int. 2008;28:271–6.PubMed
180.
El-Sherbini N, Duncan N, Hickson M, Johansson L, Brown EA. Nutrition changes in conservatively treated patients with encapsulating peritoneal sclerosis. Perit Dial Int. 2013;33:538–43.PubMedPubMedCentralCrossRef
181.
Summers AM, Clancy MJ, Syed F, et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int. 2005;68:2381–8.PubMedCrossRef
182.
Eltoum MA, Wright S, Atchley J, Mason JC. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int. 2006;26:203–6.PubMed
183.
Korte MR, Fieren MW, Sampimon DE, Lingsma HF, Weimar W, Betjes MGH. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch multicentre EPS study. Nephrol Dial Transplant. 2011;26:691–7.PubMedCrossRef
184.
De Sousa-Amorim E, Del Peso G, Bajo MA, Alvarez L, Ossorio M, Gil F, Bellon T, Selgas R. Can EPS development be avoided with early interventions? The potential of tamoxifen - a single-center study. Perit Dial Int. 2014;34:582–93.PubMedPubMedCentralCrossRef
185.
Moriishi M, Kawanishi H, Kawai T el al. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. Adv Perit Dial 2002; 18: 149-153.
186.
Yamamoto Y, Nagasue K, Okuno S, Yamakawa T. The role of peritoneal lavage and the prognostic significance of the mesothelial cell area in preventing encapsulating peritoneal sclerosis. Perit Dial Int. 2010;30:343–52.PubMedCrossRef
187.
Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing encapsulating peritonitis study group. Am J Kidney Dis. 1996;28:420–7.PubMedCrossRef
188.
Kawanishi H, Moriishi M. Epidemiology of encapsulating peritoneal sclerosis in Japan. Perit Dial Int. 2005;25(Suppl 4):S14–8.PubMed
189.
Brown MC, Simpson K, Kerssens J, Mactier R, on behalf of the Scottish Renal Registry. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin JASN. 2009;4:1222–9.
190.
Johnson DW, Cho Y, Livingston BER, Hawley CM, McDonald SP, Brown FG, Rosman JB, Bannister KM, Wiggins KJ. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int. 2010;77:904–12.PubMedCrossRef
191.
Fieren MWJA, Betjes MGH, Korte MR, Boer WH. Post transplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int. 2007;27:619–24.PubMed
192.
Korte MR, Sampimon DE, Lingsma HF, Fieren MW, Looman CWN, Zietse R. Weimar W,4 and Betjes MGH. Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study. Perit Dial Int. 2011;31:269–78.PubMedCrossRef
193.
Brown EA, Van Biesen W, Finkelstein FO, Hurst H, Johnson DW, Kawanishi H, Pecoits-Filho R, Woodrow G. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD. Perit Dial Int. 2009;29:595–600.PubMed
194.
Davies SJ, Brown B, Bryan J, Russell GI. Clinical evaluation of the peritoneal equilibration test: a population-based study. Nephrol Dial Transplant. 1993;8(1):64–70.PubMedCrossRef
195.
Ho-dac-Pannekeet MM, Atasever B, Struijk DG, Krediet RT. Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis. Perit Dial Intl. 1997;17(2):144–50.
196.
Watson PE, Watson ID, Batt RD. Total body water volume for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr. 1980;33:27–39.PubMed
197.
Woodrow G, Oldroyd B, Turney JH, Davies PSW, Day JME, Smith MA. Measurement of total body water and urea kinetic modelling in peritoneal dialysis. Clin Nephrol. 1997;47:52–7.PubMed
198.
Woodrow G, Oldroyd B, Wright A, Coward A, Truscott JG, Turney JH, Brownjohn AM, Smith MA. Comparison of anthropometric equations for estimation of total body water in peritoneal dialysis patients. Nephrol Dial Transplant. 2003;18:384–9.PubMedCrossRef
199.
McCafferty K, Fan S. Are we underestimating the problem of ultrafiltration in peritoneal dialysis patients? Perit Dial Int. 2006;26(3):349–52.PubMed
200.
La Milia V, Pozzoni P, Crepaldi C, Locatelli F. The overfill of bags for peritoneal dialysis as a cause of underestimation of ultrafiltration failure. Perit Dial Int. 2006;26(4):503–5.PubMed
201.
Warady BA, Jennings J. The short PET in pediatrics. Perit Dial Int. 2007;27(4):441–5.PubMed
202.
Morgenstern BZ, Wühl E, Nair KS, Warady BA, Schaefer F. Anthropometric prediction of Total body water in children who are on pediatric peritoneal dialysis. J Am Soc Nephrol. 2006;17:285–93.PubMedCrossRef
Metadata
Title
Renal Association Clinical Practice Guideline on peritoneal dialysis in adults and children
Authors
Graham Woodrow
Stanley L. Fan
Christopher Reid
Jeannette Denning
Andrew Neil Pyrah
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2017
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-017-0687-2

Other articles of this Issue 1/2017

BMC Nephrology 1/2017 Go to the issue

Research article

Interaction between acyl-ghrelin and BMI predicts clinical outcomes in hemodialysis patients

Research article

A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria

Research article

Statin use and hip fractures in U.S. kidney transplant recipients

Research article

Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection

Research article

Risk factors for community-acquired acute kidney injury in patients with and without chronic kidney injury and impact of its initial management on prognosis: a prospective observational study

Study protocol

The Ferumoxytol for Anemia of CKD Trial (FACT)—a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits